Wyndham H. Wilson

59.8k total citations · 6 hit papers
329 papers, 17.6k citations indexed

About

Wyndham H. Wilson is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Wyndham H. Wilson has authored 329 papers receiving a total of 17.6k indexed citations (citations by other indexed papers that have themselves been cited), including 222 papers in Pathology and Forensic Medicine, 139 papers in Genetics and 132 papers in Oncology. Recurrent topics in Wyndham H. Wilson's work include Lymphoma Diagnosis and Treatment (220 papers), Chronic Lymphocytic Leukemia Research (132 papers) and Viral-associated cancers and disorders (56 papers). Wyndham H. Wilson is often cited by papers focused on Lymphoma Diagnosis and Treatment (220 papers), Chronic Lymphocytic Leukemia Research (132 papers) and Viral-associated cancers and disorders (56 papers). Wyndham H. Wilson collaborates with scholars based in United States, Germany and United Kingdom. Wyndham H. Wilson's co-authors include Elaine S. Jaffe, Kieron Dunleavy, Maryalice Stetler‐Stevenson, Louis M. Staudt, Seth M. Steinberg, Mark Roschewski, Stefania Pittaluga, John E. Janik, Robert J. Kreitman and Ira Pastan and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Wyndham H. Wilson

318 papers receiving 17.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells

2011 1.1k citations Wyndham H. Wilson, Maryalice Stetler‐Stevenson et al. Blood profile →
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

2010 1.0k citations Wyndham H. Wilson, John E. Janik et al. Blood profile →
Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia

2001 815 citations Andreas Rosenwald, Ash A. Alizadeh et al. profile →
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

2010 663 citations Wyndham H. Wilson, Myron S. Czuczman et al. profile →
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications

2020 583 citations George W. Wright, Da Wei Huang et al. Cancer Cell profile →
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL

2021 170 citations Wyndham H. Wilson, George W. Wright et al. Cancer Cell profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Wyndham H. Wilson United States	66	9.0k	8.2k	4.8k	4.8k	4.0k	329	17.6k
Amy Chadburn United States	67	8.4k 0.9×	6.7k 0.8×	4.3k 0.9×	3.3k 0.7×	6.0k 1.5×	246	19.0k
Anas Younes United States	77	10.9k 1.2×	11.6k 1.4×	4.0k 0.8×	5.0k 1.0×	6.5k 1.7×	529	22.1k
Gianluca Gaïdano Italy	73	9.4k 1.1×	11.0k 1.3×	4.5k 0.9×	7.7k 1.6×	4.7k 1.2×	616	20.4k
Ralf Küppers Germany	69	7.1k 0.8×	10.4k 1.3×	7.9k 1.6×	5.5k 1.1×	4.0k 1.0×	264	18.9k
Michael Hummel Germany	73	7.6k 0.8×	8.4k 1.0×	4.0k 0.8×	2.7k 0.6×	3.6k 0.9×	461	18.5k
Michael Pfreundschuh Germany	70	8.3k 0.9×	10.1k 1.2×	6.5k 1.4×	4.1k 0.8×	5.7k 1.4×	421	20.6k
Andrew D. Zelenetz United States	65	8.6k 1.0×	13.8k 1.7×	3.4k 0.7×	6.0k 1.2×	2.9k 0.7×	376	19.3k
Ranjana H. Advani United States	66	10.2k 1.1×	13.5k 1.7×	4.6k 0.9×	5.5k 1.1×	2.4k 0.6×	456	20.0k
Antonino Carbone Italy	77	11.9k 1.3×	10.4k 1.3×	3.8k 0.8×	3.2k 0.7×	2.7k 0.7×	644	20.5k
Stephen M. Ansell United States	83	15.0k 1.7×	13.8k 1.7×	8.8k 1.8×	5.6k 1.2×	4.2k 1.1×	741	26.6k

Countries citing papers authored by Wyndham H. Wilson

Since Specialization

Citations

This map shows the geographic impact of Wyndham H. Wilson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wyndham H. Wilson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wyndham H. Wilson more than expected).

Fields of papers citing papers by Wyndham H. Wilson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wyndham H. Wilson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wyndham H. Wilson. The network helps show where Wyndham H. Wilson may publish in the future.

Co-authorship network of co-authors of Wyndham H. Wilson

This figure shows the co-authorship network connecting the top 25 collaborators of Wyndham H. Wilson. A scholar is included among the top collaborators of Wyndham H. Wilson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wyndham H. Wilson. Wyndham H. Wilson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Xiaohu, Patricia Alfonso, Patrick J. Morris, et al.. (2025). An Assessment of Kinase Selectivity, Enzyme Inhibition Kinetics and in Vitro Activity for Several Bruton Tyrosine Kinase (BTK) Inhibitors. PubMed Central. 8(12). 4312–4325.

Goldstein, Jordan, Mark Roschewski, Won-Seog Kim, et al.. (2024). Baseline Prognostic Factors Do Not Predict End of Treatment Ctdna MRD Status and Have Limited Impact on MRD Prognostic Performance in DLBCL. Blood. 144(Supplement 1). 651–651.

Melani, Christopher, Max J. Gordon, Stefania Pittaluga, et al.. (2024). Abstract PO-008: Phase I/II study of VIP152 (enitociclib), venetoclax, and prednisone (VVIP) in relapsed/refractory (R/R) lymphoid malignancies. Blood Cancer Discovery. 5(3_Supplement). PO–8.

Dalela, D., Stefania Pittaluga, Jagan Muppidi, et al.. (2023). IBCL-297 Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders (LPD) and EBV-Positive Non-Hodgkin Lymphomas (NHL). Clinical Lymphoma Myeloma & Leukemia. 23. S451–S451. 1 indexed citations

Roschewski, Mark, David M. Kurtz, Jason R. Westin, et al.. (2023). MRD‐NEGATIVITY AFTER FRONTLINE DLBCL THERAPY: POOLED ANALYSIS OF 6 CLINICAL TRIALS. Hematological Oncology. 41(S2). 177–179. 5 indexed citations

Wilson, Wyndham H., George W. Wright, Da Wei Huang, et al.. (2021). Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL. Cancer Cell. 39(12). 1643–1653.e3. 170 indexed citations breakdown →

Pittaluga, Stefania, Jagan Muppidi, James D. Phelan, et al.. (2021). Phase 2 Study of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas. Blood. 138(Supplement 1). 4504–4504. 8 indexed citations

Schöder, Heiko, Mei‐Yin C. Polley, Michael V. Knopp, et al.. (2020). Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. Blood. 135(25). 2224–2234. 63 indexed citations

Ahlman, Mark A., Christopher Melani, Stefania Pittaluga, et al.. (2019). Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RR. Blood. 134(Supplement_1). 4080–4080.

10.

Melani, Christopher, Mark Roschewski, Stefania Pittaluga, et al.. (2018). Phase II Study of Interferon-Alpha and DA-EPOCH+/-R in Lymphomatoid Granulomatosis. Blood. 132(Supplement 1). 785–785. 3 indexed citations

11.

Saba, Nakhle S., Delong Liu, Sarah E. M. Herman, et al.. (2016). Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood. 128(1). 82–92. 111 indexed citations

12.

Navarro, Alba, Guillem Clot, Cristina Royo, et al.. (2013). microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics. Clinical Cancer Research. 19(12). 3121–3129. 29 indexed citations

13.

Chang, Betty, Michelle Francesco, Martin F. M. de Rooij, et al.. (2013). Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 122(14). 2412–2424. 159 indexed citations

14.

Weniger, Marc A., Edgar Gil Rizzatti, Patricia Pérez‐Galán, et al.. (2011). Treatment-Induced Oxidative Stress and Cellular Antioxidant Capacity Determine Response to Bortezomib in Mantle Cell Lymphoma. Clinical Cancer Research. 17(15). 5101–5112. 82 indexed citations

15.

Landgren, Ola, James J. Goedert, Charles S. Rabkin, et al.. (2010). Circulating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma. Journal of Clinical Oncology. 28(5). 773–779. 80 indexed citations

16.

Dunleavy, Kieron, Richard F. Little, Stefania Pittaluga, et al.. (2010). The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 115(15). 3017–3024. 123 indexed citations

17.

Dunleavy, Kieron, Stefania Pittaluga, Myron S. Czuczman, et al.. (2009). Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 113(24). 6069–6076. 371 indexed citations

18.

Wilson, Wyndham H., Kieron Dunleavy, Stefania Pittaluga, et al.. (2008). Phase II Study of Dose-Adjusted EPOCH and Rituximab in Untreated Diffuse Large B-Cell Lymphoma With Analysis of Germinal Center and Post-Germinal Center Biomarkers. Journal of Clinical Oncology. 26(16). 2717–2724. 217 indexed citations

19.

Neelapu, Sattva S., Larry W. Kwak, Carol B. Kobrin, et al.. (2005). Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nature Medicine. 11(9). 986–991. 85 indexed citations

20.

Bates, Susan E., Zhiqing Zhan, Bruce Dickstein, et al.. (1994). Reversal of Multidrug Resistance. Journal of Hematotherapy. 3(3). 219–223. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact